HIA
BBIO icon

HFM Investment Advisors’s BridgeBio Pharma BBIO Stock Holding History

HFM Investment Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19K Buy
16
+7
+78% +$490 ﹤0.01% 665
2026
Q1 		$668 Hold
9
– – ﹤0.01% 556
2025
Q4 		$689 Hold
9
– – ﹤0.01% 589
2025
Q3 		$467 Hold
9
– – ﹤0.01% 689
2025
Q2 		$389 Buy
9
+6
+200% +$218 ﹤0.01% 751
2025
Q1 		$104 Buy
+3
New +$101 ﹤0.01% 843

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

HFM Investment Advisors's BBIO Position: Q2 2026 in Review

HFM Investment Advisors increased its BridgeBio Pharma (BBIO) stake by 78% in Q2 2026, buying an estimated $490 and bringing the position to 16 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #665.

HFM Investment Advisors first reported a position in BBIO in Q1 2025 and has held it in 6 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • HFM Investment Advisors held 16 shares of BridgeBio Pharma worth $1.19K as of Q2 2026.
  • HFM Investment Advisors bought 7 BridgeBio Pharma shares in Q2 2026, an estimated $490.
  • BridgeBio Pharma made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #665 holding.
  • HFM Investment Advisors first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 6 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.